Evolution of resistance to Irinotecan in cancer cells involves generation of topoisomerase-guided mutations in non-coding genome that reduce the chances of DNA breaks
S. Kumar, V. Gahramanov, S. Patel, J. Yaglom, L. Kaczmarczyk, I. Alexandrov, G. Gerlitz, M. Salmon-Divon, M. Y. Sherman
The paper investigates how cancer cells develop resistance to irinotecan by generating topoisomerase-guided mutations in non-coding regions, reducing DNA breaks and increasing drug resistance.
bioRxiv · Nov 26, 2021Cancer Biology